Molecular Partners AG
SIX:MOLN
Molecular Partners AG
Research & Development
Molecular Partners AG
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Research & Development
-CHf41.5m
|
CAGR 3-Years
19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Research & Development
-$283.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Research & Development
-CHf81.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-3%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Research & Development
-CHf98.4m
|
CAGR 3-Years
37%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Research & Development
-CHf8.6m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Research & Development
-CHf1.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Research & Development?
Research & Development
-41.5m
CHF
Based on the financial report for Sep 30, 2025, Molecular Partners AG's Research & Development amounts to -41.5m CHF.
What is Molecular Partners AG's Research & Development growth rate?
Research & Development CAGR 3Y
19%
Over the last year, the Research & Development growth was 34%. The average annual Research & Development growth rates for Molecular Partners AG have been 19% over the past three years .
